Table 3. FSDS and number of sexual encounters at baseline and during study period in PP dataset.
FSDS: female sexual distress scale; PP: per-protocol; CI: confidence interval
| Ashwagandha (AG, n=37) | Placebo (PL, n=35) | t-test | Mean Difference | 95% C.I. for diff. | Effect size (Cohen’s) | |||||
| Mean | SD | Mean | SD | t' | p' | ‘d' | 95% C.I. for ‘d’ | |||
| FSDS scale | ||||||||||
| Day 0 | 17.32 | 3.38 | 17.69 | 3.08 | -0.473 | 0.638 | -0.36 | -1.89 to 1.16 | -0.11 | -0.57 to 0.35 |
| Change at Week 4 | -6.00 | 3.11 | -3.97 | 2.73 | -2.936 | 0.004 | -2.03 | -3.41 to -0.65 | -0.69 | -1.17 to -0.21 |
| Change at Week 8 | -9.16 | 2.91 | -5.29 | 3.21 | -5.370 | <0.0001 | -3.88 | -5.32 to -2.44 | -1.27 | -1.77 to -0.75 |
| Total sexual encounters | ||||||||||
| Day 0 | 4.41 | 1.77 | 4.17 | 2.04 | 0.521 | 0.604 | 0.23 | -0.66 to 1.13 | 0.12 | -0.34 to 0.59 |
| Change at Week 4 | 0.78 | 1.18 | 0.49 | 1.80 | 0.833 | 0.407 | 0.30 | -0.42 to 1.01 | 0.197 | -0.27 to 0.66 |
| Change at Week 8 | 0.81 | 1.78 | 0.06 | 2.11 | 1.641 | 0.105 | 0.75 | -0.16 to 1.67 | 0.387 | -0.08 to 0.85 |
| Successful encounters | ||||||||||
| Day 0 | 1.76 | 0.93 | 1.89 | 1.21 | -0.510 | 0.611 | -0.13 | -0.63 to 0.37 | -0.12 | -0.58 to 0.34 |
| Change at Week 4 | 1.70 | 0.97 | 1.03 | 1.27 | 2.540 | 0.013 | 0.67 | 0.14 to 1.20 | 0.599 | 0.12 to 1.07 |
| Change at Week 8 | 2.32 | 1.08 | 1.11 | 1.08 | 4.752 | <0.0001 | 1.21 | 0.70 to 1.72 | 1.120 | 0.62 to 1.61 |